Drugs / VRN101099
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07550946 | May → Sep 2026 overdue | — | Voronoi, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06806982 | Feb 2025 → May 2026 overdue | carcinoma | Voronoi, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRN101099 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06806982 ↗ |
| Route | Oral | “VRN101099 capsules will be administered orally” NCT06806982 ↗ |